NasdaqGS:GILDBiotechs
A Look At Gilead Sciences (GILD) Valuation After FDA Priority Review For New HIV Tablet
Gilead Sciences (GILD) recently drew attention after the FDA accepted its New Drug Application for a once daily bictegravir and lenacapavir HIV tablet. The application was granted priority review, supported by Phase 3 data and positive tolerability findings.
See our latest analysis for Gilead Sciences.
The stock has reacted to the FDA priority review and upcoming earnings with a 2.11% 1 day share price return and 5.79% 7 day share price return. However, the 30 and 90 day share price returns...